30 results about "Vascular malformation" patented technology

The present disclosure provides methods of treating cerebral cavernous malformations and Devic's disease with ROCK2 inhibitors. The present disclosure also provides pharmaceutical formulations for oral administration of ROCK2 inhibitors for the treatment of cerebral cavernous malformations and Devic's disease.

Apparatus is provided for treating a vascular malformation, including an orifice section, an occlusion section, and a connecting section. When the apparatus is unconstrained, the orifice and occlusion sections are shaped so as to define orifice-section and occlusion-section curves that wind around non-coaxial orifice-section and occlusion-section central axes, respectively, at changing distances from the axes. The orifice-section curve defines an orifice-section central opening. A projection of the occlusion-section curve occludes at least 25% of a orifice-section-central-opening cross-sectional area of an orifice-section central opening; the projection of the occlusion-section curve is in a direction along the orifice-section central axis, onto an orifice-section plane perpendicular to the orifice-section central axis. Other embodiments are also described.

The invention provides a developing agent which is modified iopamidol, a clinically safe nonionic hydrophilic developing agent iopamidol is subjected to structural modification, a hydrophilic side chain and a connecting arm are introduced, and the iopamidol is introduced into a gelatin degradable microsphere matrix with good biocompatibility in a covalent bonding manner; the degradable non-ionic X-ray developing microsphere with good biocompatibility is formed. Developing microspheres prepared by adopting the developing agent provided by the invention not only keep excellent X-ray developing performance, solve the problems of aggregation tendency and biocompatibility of traditional developing microspheres and realize real-time visual monitoring of an embolism process, but also have degradability and good biological safety, and are not only suitable for permanent embolism treatment, but also suitable for treatment of embolism. The solid developing embolism agent can also be expanded to the fields of temporary embolism, tissue engineering and the like, and the solid developing embolism agent with precise developing and safe degradation performance is provided for minimally invasive interventional therapy of diseases such as tumor intervention and vascular malformation.

The present invention relates to a pharmaceutical composition for preventing or treating cerebral cavernous malformation (CCM), comprising a transient receptor potential vanilloid 4 (TRPV4) inhibitor.

The invention belongs to the technical field of pathological science, and discloses application of TLSs in preparation of a product for prognosis evaluation of complex vascular malformation. The product realizes prognosis evaluation based on parameters of maturity, distribution and quantity of TLSs in a focus of complex vascular malformation; when the number of the TLSs in the parameter is larger and the maturity is higher, the associated information of the complex vascular malformation that the disease course is longer and the recurrence possibility is high is correspondingly output. The invention provides a specific evaluation standard of the TLSs in complex vascular malformation, and a prediction application value for prompting disease prognosis recurrence of the TLSs. The TLSs can be used as a pathological index for detecting recurrence prognosis by FAVA and PHOST, and the risk of postoperative recurrence of vascular malformation can be predicted by detecting the distribution, the number and the maturity of the TLSs. For pathologists with rich experiences, the maturity of TLSs can be evaluated according to HE slices, and the method has good sensitivity and specificity.

The invention relates to a medicine for preventing and treating cerebral cavernous malformation lesion and application thereof. The invention discloses a medicine which can inhibit the occurrence and growth of a cerebral cavernous malformation focus by inhibiting a molecular pathway of CCM, and also comprises analogues or derivatives of the medicine. The treatment of the CCM generally takes the brain as a drug target, the lower toxic and side effects particularly need to be concerned, and the drug disclosed by the invention has low side effects. The medicine provided by the invention can limit the occurrence of lesions in the initial stage of CCM, and is also suitable for preventing the progress of advanced lesions.

The invention relates to the technical field of biomedical materials, and provides zeolite polyvinyl alcohol organic-inorganic composite embolization microspheres as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing nano zeolite with a blood coagulation function through ion exchange, dispersing the nano zeolite in silicone oil to form a continuous phase, and forming W / O type liquid drops from a polyvinyl alcohol dispersed phase solution and the continuous phase containing the nano zeolite by adopting a microfluidic technology; and crosslinking and curing by using an organic acid catalyst to obtain the zeolite polyvinyl alcohol organic-inorganic composite embolism microsphere with a physical embolism function and a procoagulant function. The zeolite polyvinyl alcohol organic-inorganic composite embolism microsphere takes cross-linked polyvinyl alcohol as a matrix, nano zeolite particles with specific functions are uniformly distributed on the surface, and the zeolite polyvinyl alcohol organic-inorganic composite embolism microsphere has a physical embolism function and a procoagulant function and has a wide application prospect in the fields of tumor embolism treatment, vascular malformation embolism, hemorrhagic disease treatment and the like; and a brand-new efficient embolism treatment solution is provided for clinic.

The present application provides use of a PI3Kα inhibitor in the manufacture of a medicament for treating a disease associated with a PIK3CA or / and TEK gene mutation. In particular, the present application provides use of a PI3Kα inhibitor CYH33 or a pharmaceutical composition comprising CYH33 in the manufacture of a medicament for preventing, treating or alleviating a PIK3CA-related overgrowth syndrome (PROS) and / or a PIK3CA-related vascular malformation (PRVM), and / or a TEK gene mutation-related vascular malformation.

Described herein is a patch delivery assembly for treating a target site and a method for deploying the same. The patch delivery assembly includes a patch installation frame having a self-expanding body extending between a proximal end and an open distal end and defining a lumen therethrough. The patch delivery assembly also includes a delivery cable having a distal end coupled to the proximal end of the patch installation frame and further defining the lumen, and a securement device extending through the lumen defined through the delivery cable and the patch installation frame, the securement device terminating in a distal working end including a securement mechanism. In a deployment configuration of the patch delivery assembly, the patch delivery assembly further includes a patch releasably coupled to the distal end of the patch installation frame, for securement to tissue of the target site using the securement mechanism.

The application provides application of bevacizumab in preparation of a medicine for inhibiting hemorrhagic lesions of cerebral vascular malformations, and belongs to the technical field of medicine application. The application firstly discovers and proves by experiments that bevacizumab can be used for binding free VEGF molecules in serum of a patient with a cavernous cerebral vascular malformation, thereby inhibiting a VEGF path, and having obvious inhibiting effect on symptomatic hemorrhagic lesions of the cavernous cerebral vascular malformation, and developing a new use of bevacizumab, and providing a new selection of drug treatment for the patient with the cavernous cerebral vascular malformation.

The application discloses a novel OCT space reconstruction method, which comprises the following steps: acquiring multiple coronary angiography image data at different angles; extracting coronary angiography images at the same moment in different cardiac cycles from the coronary angiography image data acquired at each angle; extracting a blood vessel skeleton according to the coronary angiography images; in the process of extracting the blood vessel skeleton, the coronary angiography images at different angles are included; multi-view stereo matching is performed by using deep learning, and matching correction is performed by using an epipolar geometry algorithm; a three-dimensional blood vessel skeleton is acquired according to the coronary angiography images after the matching correction; coronary OCT sequence images are acquired, and rearrangement is performed in combination with the direction of the three-dimensional blood vessel skeleton; body rendering is performed on the rearranged images, and a three-dimensional space model with a real posture is rendered. The method realizes prediction of invisible parts and guarantees the correctness of three-dimensional reconstruction of visible parts, and provides a data basis for screening of vascular deformity and the like in the later stage.

The present disclosure relates to a system for identifying the gene mutation type of a cerebral cavernous malformation (CCM) patient, and a system for determining a treatment plan for a cerebral cavernous malformation patient. The system provided by the present disclosure can determine the gene mutation type of a cerebral cavernous malformation patient based on a head computed tomography (CT) image and / or a magnetic resonance imaging (MRI) of the cerebral cavernous malformation patient, and therefore, the present disclosure provides a non-invasive method for determining the corresponding gene mutation type of a CCM patient, enriches the diagnosis method of CCM, and can provide a strong basis for the rationalization and targeted treatment of CCM.

The invention relates to a device (17) for treatment of body tissue, in particular for the permanent occlusion of varicose veins, preferably in the lower limbs, of varicocele and / or of vascular malformations and / or for the use in aesthetic surgeries, preferably laser assisted lipolysis, and / or for tumor treatment by means of laser induced thermotherapy and / or photodynamic therapy, and / or in particular for the irradiation of brain tissue, for ear-nose-throat applications, in particular necrosis of tissue, for surface disinfection by laser light, for dermatologic treatment, including application on skin and / or nails and / or for treatment of pilonidal sinus, anal fistula and / or hemorrhoids, by means of a light diffuser (13) for irradiating said tissue by laser light energy and / or by electromagnetic radiation, wherein the light diffuser (13) is designed to irradiate the radiation laterally with respect to a longitudinal center axis of the light diffuser (13) and endoluminally. According to the invention, a sliding layer (51) is provided on an outer surface, in particular the outermost surface, of a distal end of the diffuser (13) at least in certain regions, preferably in the region of the front distal end of the diffuser (13) and / or in the region of the energy emission of the diffuser (13), in particular completely, in particular to reduce friction with and / or in particular to reduce adhesion to said surrounding tissue.

The disclosure relates in part to the discovery that slow-flow vascular malformations (which can be venous and / or lymphatic) can be treated using direct intralesional delivery of an active drug, such as but not limited to a mTOR inhibitor, such as but not limited to temsirolimus, or a salt or solvate thereof.

An apparatus is provided for treating a vascular malformation. The apparatus includes an orifice section, an intra-vascular-malformation docking section, and a connecting section. The apparatus is configured such that, when unconstrained the orifice section is shaped so as to define an orifice-section curve that winds at least 2.5 turns around an orifice-section central axis at a changing distance from the orifice-section central axis, the intra-vascular-malformation docking section is shaped so as to define a docking-section curve that winds between 0.5 and 2 turns around a docking-section central axis at a changing or constant distance from the docking-section central axis, and a slope of the connecting-section is greater than a slope of the orifice-section. Other embodiments are also described.

Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.

Described herein are methods of selectively targeting a cell expressing upregulated PI3K activity in a subject, the method comprising: administering to the subject a plurality of nanoparticles having an average diameter between 60 nm to 200 nm, the nanoparticles comprising: a polymer; and, one or more a pharmaceutical agents. In embodiments, the methods are for the treatment of vascular malformations or cancer.

The invention provides a gene detection kit for molecular diagnosis of hemangioma and vascular malformation and application. Specifically, the invention provides a gene combination for determining molecular diagnosis of hemangioma and vascular malformation, and based on NGS panel + RNAseq gene sequencing, the gene combination for molecular diagnosis of hemangioma and vascular malformation provided by the invention can be applied to all molecular diagnosis and liquid biopsy related to hemangioma and vascular malformation. The correlation between mutation sites and abundance and disease phenotypes is disclosed, so that the method has a relatively great clinical popularization and application prospect.

The disclosure relates in part to the discovery that slow-flow vascular malformations (which can be venous and / or lymphatic) can be treated using direct intralesional delivery of an active drug, such as but not limited to a mTOR inhibitor, such as but not limited to temsirolimus, or a salt or solvate thereof.

In one aspect, the present invention features a method of inhibiting proliferation and / or reducing survival of a cell comprising a GNAQ polynucleotide or polypeptide having a R183Q or Q209L mutation, comprising contacting the cell with puromycin or a puromycin analog, thereby inhibiting proliferation and / or reducing survival of the cell. In another aspect, a method of treating a vascular malformation or related condition in a subject, comprising administering to the subject an effective amount of puromycin or a puromycin analog is featured. In another aspect, the present invention features a method of identifying a candidate agent that modulates a GNAQ R183Q or Q209L mutation-associated disease, comprising contacting a cell comprising a GNAQ polynucleotide or polypeptide having a R183Q or Q209L mutation with puromycin and a candidate agent and comparing viability of the contacted cell with a reference level of viability, wherein an alteration in viability indicates that the candidate agent modulates the GNAQ R183Q or Q209L mutation-associated disease.

The invention belongs to the field of biological detection, and discloses a gene detection panel for detecting hemangioma and vascular malformation and application of the gene detection panel. The invention discloses a gene detection panel for hemangioma and vascular malformation. Comprising the gene detection panel and is used for detecting hemangioma and vascular malformation; an application of the gene detection panel in preparation of a hemangioma and vascular malformation diagnostic reagent or diagnostic kit; the gene detection panel is applied to a device for auxiliary diagnosis of etiology of hemangioma and vascular malformation patients; and the device is used for auxiliary diagnosis of pathogenesis of hemangioma and vascular malformation patients. The gene detection panel disclosed by the invention can efficiently and accurately identify gene mutation related to hemangioma and vascular deformity, can cover wide genes related to hereditary and sporadic vascular deformity, and can provide accurate information for diagnosis, treatment and prognosis evaluation of diseases.

The application discloses a method for training a prediction model for a bleeding risk and related products. The method comprises: collecting medical image data, genotypes and bleeding risk labels of a subject, wherein the medical image data is labeled with a bleeding mask and a classification type of cerebral cavernous malformations; based on the medical image data, feature extraction is performed using the feature extraction unit to obtain image features; the genotypes are embedded into the image features using the embedding unit to obtain embedded features; the embedded features are input into the prediction unit for bleeding risk prediction and classification prediction, and a loss function is calculated based on the bleeding risk labels and the classification type; and the prediction model is trained based on the loss function, so that the prediction unit outputs bleeding risk prediction results and classification prediction results. The scheme of the application can improve accurate bleeding risk and classification prediction, and provide comprehensive decision support for clinics.

The invention provides a blood vessel deformity degree evaluation method based on confocal endoscope imaging hemodynamic parameters, and relates to the technical field of artificial intelligence medical treatment, the method comprises two stages: imaging stable stage screening: collecting a blood vessel examination video through a confocal laser microendoscope; screening out image stable fragments in the blood vessel examination video according to dynamic change and velocity dynamics characteristics of red blood cells in the blood vessel; and malformation blood vessel evaluation: performing video frame extraction processing on the image stable segment to obtain multiple frames of images, analyzing the blood vessel malformation condition in each frame of image in combination with haemodynamic parameters and blood vessel morphology, labeling the blood vessel malformation segment, quantifying the malformation degree of the blood vessel malformation segment, and evaluating the blood vessel malformation. According to the method provided by the invention, the blood vessel abnormality is evaluated by combining the hemodynamic parameters and the blood vessel morphology, and the efficiency and accuracy of blood vessel abnormality detection can be effectively improved.

The invention belongs to the field of biological detection, and discloses a gene detection panel for detecting hemangioma and vascular malformation and application of the gene detection panel. The invention discloses a gene detection panel for hemangioma and vascular malformation. Comprising the gene detection panel and is used for detecting hemangioma and vascular malformation; an application of the gene detection panel in preparation of a hemangioma and vascular malformation diagnostic reagent or diagnostic kit; the gene detection panel is applied to a device for auxiliary diagnosis of etiology of hemangioma and vascular malformation patients; and the device is used for auxiliary diagnosis of pathogenesis of hemangioma and vascular malformation patients. The gene detection panel disclosed by the invention can efficiently and accurately identify gene mutation related to hemangioma and vascular deformity, can cover wide genes related to hereditary and sporadic vascular deformity, and can provide accurate information for diagnosis, treatment and prognosis evaluation of diseases.

The invention provides application of aspelisib in preparation of a medicine for treating cavernous malformation of a central nervous system, in particular to family type cavernous malformation, preferably cavernous malformation related to functional inactivation mutation of KRIT1 (CCM1), CCM2 or PDCD10 (CCM3) genes, and particularly relates to application of aspelisib in preparation of a medicine for treating cavernous malformation of a central nervous system. Asperisib can effectively inhibit the formation of cavernous vascular deformity lesion of the central nervous system of a mouse and reduce the occurrence of vascular deformity and the volume of the lesion, and a new application of Asperisib is added clinically.

The invention relates to the technical field of biomedicine and gene therapy, in particular to application of Krit1 mRNA in treatment of cerebral cavernous malformation. The KRIT1 mRNA forms LNP (at) Krit1 mRNA through the lipid nanoparticles for delivery, and can be applied to preparation of a reagent for preventing and / or treating cerebral cavernous malformation, preparation of a barrier function reagent for recovering cerebral vascular endothelial cells and preparation of a reagent for reducing or inhibiting leakage and bleeding of brain blood vessels; the Krit1 function can be effectively recovered in both in-vitro and in-vivo CCM models, vasculopathy is remarkably improved, and the Krit1 gene has good development prospects and clinical transformation value.

The invention discloses a method for training a prediction model for bleeding risk and a related product. The method comprises the following steps: collecting medical image data, genotype and bleeding risk label of a detected person, wherein the medical image data is marked with a bleeding mask and the typing type of brain cavernous vessel deformity; based on the medical image data, performing feature extraction by using the feature extraction unit to obtain image features; embedding the genotype into the image feature by using the embedding unit to obtain an embedded feature; inputting the embedded features into the prediction unit to perform bleeding risk prediction and typing prediction, and calculating a loss function based on the bleeding risk tag and the typing type; and training the prediction model based on the loss function, so that the prediction unit outputs a bleeding risk prediction result and a typing prediction result. By using the scheme of the invention, accurate bleeding risk and typing prediction can be improved, and comprehensive decision support is provided for clinic.

The invention relates to the technical field of medicine, and particularly discloses a foam hardening agent for treating low-flow-rate vascular malformation and a preparation method thereof, the foam hardening agent comprises a drug conjugate, a stabilizer, a water-soluble enhancer, foaming gas and an injection solvent; according to the drug conjugate, citric anhydride is bridged with lauromacrogol and bleomycin to form a covalent structure, so that the problems of non-uniform drug distribution and poor synergism during physical mixing are solved. The preparation method comprises the following steps: synthesizing a conjugate through esterification and amidation reactions, mixing the conjugate with auxiliary materials, and foaming through a Tesari method. The two drugs are bridged through the citric anhydride to form a conjugate which can be synergistically slowly released in a focus microenvironment, the curative effect is remarkably improved, meanwhile, the single drug dosage and toxic and side effects are reduced, and the foam preparation is high in stability, clear in development and suitable for precise interventional therapy guided by color ultrasound.

This invention discloses a method and system for assessing the risk of hemorrhage in cerebral cavernous malformations. It acquires patient lesion classification data and hemorrhage history, integrates image coding and hemorrhage event characteristics, identifies pseudo-improvement segments, performs compensation corrections to construct a risk feature vector, and extracts the hemorrhage interval rhythm to form an interval marker. The risk feature vector defines the danger level, and evolution markers are obtained based on the danger level. A stratified early warning criterion set is established by combining the interval markers with hierarchical extrapolation. An induction index is determined based on the interaction effect between the interval markers and the danger level, and a propensity correction value is formed through risk trigger mapping and adaptive correction. The propensity correction value is used to review the treatment sequence and assess the intervention safety margin, matching the intervention timing to determine the intervention plan. The early warning criterion set and the propensity correction value are correlated and integrated for time-series extrapolation to form hemorrhage time window parameters. Combined with the intervention plan scenario adaptation, a hemorrhage risk assessment report is generated, providing systematic support for individualized clinical intervention decisions.